Synonym
Pirozadil; Pemix; 722D
IUPAC/Chemical Name
(6-{[(3,4,5-trimethoxybenzoyl)oxy]methyl}-2-pyridinyl)methyl 3,4,5-trimethoxybenzoate
InChi Key
DIIBXMIIOQXTHW-UHFFFAOYSA-N
InChi Code
1S/C27H29NO10/c1-31-20-10-16(11-21(32-2)24(20)35-5)26(29)37-14-18-8-7-9-19(28-18)15-38-27(30)17-12-22(33-3)25(36-6)23(13-17)34-4/h7-13H,14-15H2,1-6H3
SMILES Code
O=C(OCC1=NC(COC(C2=CC(OC)=C(OC)C(OC)=C2)=O)=CC=C1)C3=CC(OC)=C(OC)C(OC)=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Pirozadil is a hypolipidemic agent.
In vivo activity:
The effect of pirozadil, a new hypolipidemic agent, on cerebral blood flow was tested in anesthetized dogs and compared to that of two other hypolipidemic/antiatherogenic agents, nicotinic acid and pyridinol carbamate. Pirozadil's effect on increasing cerebral blood flow was almost equal to that of papaverine, less than that of nicardipine and much greater than that of the other hypolipidemic/antiatherogenic drugs, nicotinic acid and pyridinol carbamate. Pirozadil was also shown to significantly diminish vascular cerebral resistance to a much greater degree than nicotinic acid and pyridinol carbamate.
Reference: Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401. https://pubmed.ncbi.nlm.nih.gov/7329165/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
25.0 |
47.39 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
527.53
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Roca J, Grau M, Balasch J. Effect of pirozadil on cerebral blood flow in anesthetized dogs. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401. PMID: 7329165.
In vivo protocol:
Roca J, Grau M, Balasch J. Effect of pirozadil on cerebral blood flow in anesthetized dogs. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401. PMID: 7329165.
1: Masana L, Escobar A, Joven J, Solá R, Vilella E, Bargallo T, Turner PR. Treatment of diet-resistant polygenic hypercholesterolaemic patients with a new nicotinate derivative; in vivo and in vitro low density lipoprotein metabolic studies. J Clin Pharmacol. 1989 Mar;29(3):201-6. doi: 10.1002/j.1552-4604.1989.tb03313.x. PMID: 2723106.
2: Cuchi de la Cuesta C, Cuchi Alfaro MT, Cuchi Alfaro C. Evaluación clínica del pirozadil administrado ininterrumpidamente durante 4.5 años a pacientes con hiperlipoproteinemia tipo IIa [Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa]. Rev Clin Esp. 1989 Jan;184(1):24-6. Spanish. PMID: 2704867.
3: Eficacia y tolerancia del pirozadil a largo plazo. Estudio de farmacovigilancia. Grupo de Farmacovigilancia del Pirozadil [Efficacy and tolerance to pirozadil over a long term. Drug surveillance study. The Pirozadil Drug Surveillance Group]. Med Clin (Barc). 1987 Dec 12;89(20):858-60. Spanish. PMID: 3448438.
4: Shinomiya M, Ishikawa Y, Shirai K, Saito Y, Yoshida S. Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia. Arzneimittelforschung. 1987 Sep;37(9):1069-71. PMID: 3435604.
5: Tapounet R, Marti Ragué I. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain. Drugs Exp Clin Res. 1987;13(7):447-50. PMID: 3652931.
6: Morishita S, Saito T, Mishima Y, Mizutani A, Hirai Y, Koyama S, Kawakami M. [Strains and species differences in experimental hyperlipidemia]. Nihon Yakurigaku Zasshi. 1986 Mar;87(3):259-64. Japanese. doi: 10.1254/fpj.87.259. PMID: 3458657.
7: Alberola Candel V, Labiós Gómez M, Rodrigo Benito C, Camps Herrero C, Palau Martínez F. Acción antiplaquetaria del pirozadil [Antiplatelet action of pirozadil]. Med Clin (Barc). 1984 Feb 18;82(6):253-5. Spanish. PMID: 6708647.
8: Pedraz de Cabo J. Farmacología clínica del pirozadil [Clinical pharmacology of pirozadil]. Rev Clin Esp. 1982 Oct 15;167(1):15-8. Spanish. PMID: 7178579.
9: Pedraz de Cabo J. Farmacología experimental del pirozadil. Estudio comparativo de la acción del producto sobre la lipolisis inducida, a partir de la grasa epididimaria en ratas [Experimental pharmacology of pirozadil. Comparative study of the action of the product on induced lipolysis in the epididymal fat of rats]. Rev Clin Esp. 1982 Oct 15;167(1):11-3. Spanish. PMID: 6294758.
10: Marín Plaza R, Díaz González JM, Varela de Seijas JR. Ensayo clínico con pirozadil (722-D), nueva sustancia de propiedades antiateroscleróticas [Clinical trial of a new drug for the treatment of atherosclerosis: pirozadil (722-D) (author's transl)]. Med Clin (Barc). 1982 May 16;78(10):427-32. Spanish. PMID: 7047924.
11: Cadierno Carpintero M, Emeterio Reig E, Soler Masana JM. Estudio doble ciego con un nuevo producto hipolipidemiante, el pirozadil (722-D), desde el punto de vista comparativo con alufibrato en enfermos afectos de cardiopatía isquémica [A double blind study of the new hypolipidemic agent pirozadil (722-D) using patients with ischemic heart disease (author's transl)]. Med Clin (Barc). 1982 May 1;78(9):386-9. Spanish. PMID: 7047927.
12: Honorato Pérez J, Azanza Perea JR. Estudio simple ciego sobre la eficacia del pirozadil versus alufibrato en el tratamiento de las hiperlipoproteinemias primarias [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. Rev Med Univ Navarra. 1982 Mar;26(1):51-4. Spanish. PMID: 7111953.
13: Roca J, Grau M, Balasch J. Effect of pirozadil on cerebral blood flow in anesthetized dogs. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401. PMID: 7329165.
14: Roca J, Grau M, Balasch J. Estudio de la toxicidad crónica e histopatología del pirozadil en rata [Chronic toxicological studies and histopathology of pirozadil in the rat (author's transl)]. Arch Farmacol Toxicol. 1980 Apr;6(1):41-50. Spanish. PMID: 7387202.
15: Parwaresch MR, Haacke H, Mäder C. Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds. Atherosclerosis. 1978 Dec;31(4):395-401. doi: 10.1016/0021-9150(78)90134-x. PMID: 215172.
16: Balasch J, Palacios L. Estudio de la acción del pirozadil sobre el flujo metabólico cerebral en el conejo [Effects of pirozadil on metabolic blood flow in brain rabbit (author's transl)]. Arch Farmacol Toxicol. 1977 Aug;3(2):137-40. Spanish. PMID: 921334.
-GSK-3685032 4929.jpg "(R)-GSK-3685032")